FIELD: medicine.
SUBSTANCE: invention is related to derivatives of isothiourea of formula I, including their pharmaceutically acceptable salts, which possess properties of antagonist CXCR4. In compounds of formula I , where R1 means remainder of formula (a) , (b) or (c) , R2 means -(CR22R23)1-3-, R3 and R8 each means S, R4 and R5 each independently means C3-C12cycloalkyl, C1-C12alkyl or saturated C8-C12 polycyclic hydrocarbon remainder, such as adamantine, non-substituted phenyl or non-substituted benzyl unnecessarily substituted with group R25, R6 means H or C1-C6alkyl, R7 means CH, R9 means direct connection or -(CR22R23)1-2-, R10-R15 each means H, R16-R23 each independently means H, C1-C6alkyl, or R20 and R21 together with carbon atoms, to which they are connected, create a benzene ring, and R25 has one of values given above for R16-R23.
EFFECT: improved method for production of derivatives of isothiourea.
5 cl, 1 tbl, 24 ex
Title | Year | Author | Number |
---|---|---|---|
COMBINATION CONTAINING IRON COMPLEX AND ANTINEOPLASTIC AGENT, AND USE THEREOF | 2007 |
|
RU2469721C2 |
PYRROLOPYRIMIDINE DERIVATIVES APPLICABLE IN TREATING PROLIFERATIVE DISEASES | 2005 |
|
RU2367662C2 |
COMBINATIONS INCLUDING EPOTHILONES AND THEIR PHARMACEUTICAL APPLICATION | 2003 |
|
RU2379032C9 |
COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
TREATING TUBEROUS SCLEROSIS | 2007 |
|
RU2473343C2 |
APPLICATION OF IMIDAZOQUINOLINES FOR TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH AQUIRED RESISTANCE TO AGENTS BINDING MEMBERS OF EGFR FAMILY | 2008 |
|
RU2481838C2 |
APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
COMBINATION OF PYRIMIDYLAMINOBENZAMIDE AND mTOR KINASE INHIBITOR | 2006 |
|
RU2443418C2 |
COMBINATION OF (A) PHOSPHOINOSITIDE-3-KINASE INHIBITOR AND (B) Ras/Raf/Mek PATHAWAY MODULATOR | 2009 |
|
RU2508110C2 |
PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR NEUROFIBROMATOSIS | 2006 |
|
RU2450814C2 |
Authors
Dates
2009-12-20—Published
2005-02-25—Filed